# Haya Ascher‐Svanum

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/haya-ascher-svanum/

## Facts

| Field | Value |
| --- | --- |
| Citations | 5,631 |
| Field | Schizophrenia research and treatment |
| h-index | 43 |
| i10-index | 99 |
| Last Known Institution | Eli Lilly (United States) |
| OpenAlex ID | https://openalex.org/A5011706362 |
| Works | 233 |

## Researcher papers

- [Medication Adherence and Long-Term Functional Outcomes in the Treatment of Schizophrenia in Usual Care](https://scholariq.org/papers/medication-adherence-and-long-term-functional-outcomes-in-the-treatment-of/)
- [The burden of depressive symptoms in the long-term treatment of patients with schizophrenia](https://scholariq.org/papers/the-burden-of-depressive-symptoms-in-the-long-term-treatment-of-patients-with/)
- [The cost of relapse and the predictors of relapse in the treatment of schizophrenia](https://scholariq.org/papers/the-cost-of-relapse-and-the-predictors-of-relapse-in-the-treatment-of/)
- [Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics](https://scholariq.org/papers/antipsychotic-monotherapy-and-polypharmacy-in-the-naturalistic-treatment-of/)
- [Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia](https://scholariq.org/papers/early-response-to-antipsychotic-drug-therapy-as-a-clinical-marker-of-subsequent/)
- [Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia☆](https://scholariq.org/papers/predicting-response-to-atypical-antipsychotics-based-on-early-response-in-the/)
- [Medication Nonadherence and Treatment Outcome in Patients With Schizophrenia or Schizoaffective Disorder With Suboptimal Prior Response](https://scholariq.org/papers/medication-nonadherence-and-treatment-outcome-in-patients-with-schizophrenia-or/)
- [A Prospective Study of Risk Factors for Nonadherence With Antipsychotic Medication in the Treatment of Schizophrenia](https://scholariq.org/papers/a-prospective-study-of-risk-factors-for-nonadherence-with-antipsychotic/)
- [Characteristics and Use Patterns of Patients Taking First-Generation Depot Antipsychotics or Oral Antipsychotics for Schizophrenia](https://scholariq.org/papers/characteristics-and-use-patterns-of-patients-taking-first-generation-depot/)
- [Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia](https://scholariq.org/papers/time-to-discontinuation-of-atypical-versus-typical-antipsychotics-in-the/)
- [Effect of diabetes on caregiver burden in an observational study of individuals with Alzheimer’s disease](https://scholariq.org/papers/effect-of-diabetes-on-caregiver-burden-in-an-observational-study-of-individuals/)

## Researcher topics

- [Schizophrenia research and treatment](https://scholariq.org/topics/schizophrenia-research-and-treatment/)
- [Treatment of Major Depression](https://scholariq.org/topics/treatment-of-major-depression/)
- [Mental Health and Psychiatry](https://scholariq.org/topics/mental-health-and-psychiatry/)
- [Healthcare Decision-Making and Restraints](https://scholariq.org/topics/healthcare-decision-making-and-restraints/)
- [Bipolar Disorder and Treatment](https://scholariq.org/topics/bipolar-disorder-and-treatment/)

## Researcher university

- [Eli Lilly (United States)](https://scholariq.org/institutions/eli-lilly-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.